A resolution expressing support for the designation of June 19, 2025, as "World Sickle Cell Awareness Day" in order to increase public awareness across the United States and global community about sickle cell disease and the continued need for empirical research, early detection screenings, novel effective treatments leading to a cure, and preventative care programs with respect to complications from sickle cell anemia and conditions relating to sickle cell disease.

This resolution supports the designation of June 19, 2025, as "World Sickle Cell Awareness Day," aiming to significantly increase public awareness across the United States and the global community regarding sickle cell disease (SCD). It emphasizes the critical need for continued empirical research, early detection screenings, the development of novel effective treatments leading to a cure, and robust preventative care programs to manage complications from SCD. The Senate commits to ensuring equitable access to new SCD treatments for all economic, racial, and ethnic groups, striving to improve health outcomes for individuals living with the disease. It specifically calls on the Department of Health and Human Services to develop global policy solutions and partner with local governments to provide access to newborn screening programs, therapeutic interventions, and support services for SCD. Furthermore, the resolution advocates for eliminating barriers to equitable access for innovative SCD therapies, including cell, gene, and gene-editing treatments, within the Medicare and Medicaid systems for vulnerable patients. It encourages people worldwide to organize appropriate programs and events on World Sickle Cell Awareness Day to raise awareness about SCD traits, preventative care, treatments, and patient services. Finally, the resolution encourages the President to establish a Sickle Cell Disease Interagency Group , comprising key federal agencies, to develop policies that support equitable and appropriate access to innovative SCD therapies. This group is also urged to consider options that address not only access to potential future curative treatments but also the persistent bias faced by the SCD-affected population within healthcare systems globally.